 - To study the ability of reslizumab to reduce the number of eosinophilic clinical asthma exacerbations CAE in subjects with asthma. A CAE is defined as a 20 decrease in forced expiratory volume in 1 second FEV1; absolute value from the baseline value or a requirement for emergency treatment of asthma, hospital admission for asthma or treatment with three or more days of oral corticosteroids OCS for asthma worsening. 